United Therapeutics Corp
NASDAQ:UTHR
United Therapeutics Corp
Revenue
United Therapeutics Corp
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
United Therapeutics Corp
NASDAQ:UTHR
|
Revenue
$2.3B
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
United Therapeutics Corp
Revenue Breakdown
Breakdown by Geography
United Therapeutics Corp
Total Revenue:
2.3B
USD
|
United States:
2.2B
USD
|
Rest-Of-World:
125.3m
USD
|
Breakdown by Segments
United Therapeutics Corp
Total Revenue:
2.3B
USD
|
Total Tyvaso:
1.2B
USD
|
Tyvaso Dpi:
731.1m
USD
|
Nebulized Tyvaso:
502.6m
USD
|
Remodulin:
494.8m
USD
|
Orenitram:
359.4m
USD
|
Unituxin:
198.9m
USD
|
Adcirca:
28.9m
USD
|
Other:
11.8m
USD
|
See Also
What is United Therapeutics Corp's Revenue?
Revenue
2.3B
USD
Based on the financial report for Dec 31, 2023, United Therapeutics Corp's Revenue amounts to 2.3B USD.
What is United Therapeutics Corp's Revenue growth rate?
Revenue CAGR 10Y
8%
Over the last year, the Revenue growth was 20%. The average annual Revenue growth rates for United Therapeutics Corp have been 16% over the past three years , 7% over the past five years , and 8% over the past ten years .